HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
LENZ
LENZ Therapeutics, Inc.
There isn't enough reported data to score LENZ yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
LENZ Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Weak | |
| Unavailable |
LENZ's profitability and cash flow are currently weak. There isn't enough data to rate its revenue and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
LENZ PE Valuation
LENZ has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
LENZ Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LENZ's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
LENZ has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus LENZ down 164%.
LENZ Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$7.11 | +$8.43 |
| Q2 2024 | -$9.46 | +$6.50 |
| Q1 2024 | -$15.85 | -$3.32 |
| Q4 2023 | -$15.33 | -$2.45 |
LENZ is still losing money, but far less than before: $4.53 per share over the past year, against $15.96 at its worst in mid-2023.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over LENZ in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over LENZ on profitability, with a higher operating margin.
LENZ Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3.4M | -73% |
| Q2 2026 | $5.5M | +9.7% |
LENZ's revenue has slid since its 2025 peak: $3M last quarter, down 73% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -973% | -822 points |
| Q2 2026 | -623% | -286 points |
| Q1 2026 | -2322% | N/A |
| Q4 2025 | -2422% | N/A |
| Q3 2025 | -151% | N/A |
| Q2 2025 | -337% | N/A |
LENZ's operating margin was −973% last quarter, down 822 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over LENZ on cash generation, producing positive trailing cash flow while its opponent burns cash.
LENZ Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$22.3M | -$13.3M |
| Q2 2026 | -$38.7M | -$27M |
| Q1 2026 | -$33.6M | -$17.4M |
| Q4 2025 | -$33.1M | -$23.8M |
| Q3 2025 | -$9M | +$1.7M |
| Q2 2025 | -$11.7M | +$4.2M |
| Q1 2025 | -$16.2M | +$7.8M |
| Q4 2024 | -$9.2M | +$36.7M |
LENZ has burned cash in almost every quarter: −$128M over the past year, against −$46M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over LENZ on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
LENZ Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +45.8K shares |
| 1 year | +10% | +2.9M shares |
| 3 years | +288% | +23.3M shares |
| 5 years | +279% | +23.1M shares |
LENZ has 31M diluted shares, up 10% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q2 2020 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
LENZ Net Leverage
LENZ's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
LENZ Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.6 | Neutral |
| Stochastic | 17.3 | Oversold |
LENZ's weekly RSI is 38 (neutral) and its Stochastic is 17 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
LENZ PE vs Healthcare Sector
LENZ has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
LENZ Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 16% above |
| 20 week MA | $4.50 | 9.1% below |
| 50 week MA | $9.12 | 55% below |
| 100 week MA | $19.7 | 79% below |
| 200 week MA | $18.1 | 77% below |
LENZ has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over LENZ on returns for 2026, with the stronger performance.
LENZ Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $87.6 | $54.7 | -37% |
| 2022 | $54.7 | $13.4 | -76% |
| 2023 | $13.4 | $12.4 | -7.3% |
| 2024 | $12.4 | $31.3 | +153% |
| 2025 | $31.3 | $16.9 | -46% |
| 2026 YTD | $16.9 | $4.09 | -76% |
LENZ's yearly returns have swung widely, from +153% in 2024 to −76% in 2022. It's down 76% so far in 2026.